Drug
Brincidofovir clinical trials
Also written CMX001.
- studies test it
- 22
- open now
- 2
- in phase 3
- 6
- first study started
- 2008
Keep track of what changes. Save the brincidofovir studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
22 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 11
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 1
Chimerix (14) · SymBio Pharmaceuticals (5) · Emergent BioSolutions (1) · ViiV Healthcare (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses brincidofovir is read from its arms, and is right about nine times in ten.
Testing it · 22
- A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCTRecruitingPhase 3SymBio PharmaceuticalsNCT07387367Written as Brincidofovir
- Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot StudyRecruitingPhase 2National Institute of Neurological Disorders and Stroke (NINDS)NCT07511049Written as Brincidofovir
- A Phase 2a Study of IV BCV in Subjects With Adenovirus InfectionCompletedPhase 2SymBio PharmaceuticalsNCT04706923Written as BCV
- A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell LymphomaSuspendedPhase 1/2SymBio PharmaceuticalsNCT06761677Written as Brincidofovir
- Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy AdultsCompletedPhase 1Emergent BioSolutionsNCT05935917Written as Brincidofovir
- Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney TransplantationTerminatedPhase 2SymBio PharmaceuticalsNCT05511779Written as Brincidofovir
- Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy SubjectsCompletedPhase 1ChimerixNCT05391724Written as CMX001
- CMX001 in Post-transplant Patients With BK Virus ViruriaCompletedPhase 1/2ChimerixNCT00793598Written as Brincidofovir
- Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus InfectionCompletedPhase 3ChimerixNCT02087306Written as Brincidofovir
- Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA VirusesCompletedPhase 3ChimerixNCT01143181Written as Brincidofovir
- Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus DiseaseCompletedPhase 2ChimerixNCT01241344Written as Brincidofovir
- A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT RecipientsCompletedPhase 3ChimerixNCT01769170Written as Brincidofovir
- Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus ViremiaWithdrawnPhase 2ChimerixNCT03532035Written as Brincidofovir
- Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant RecipientsCompletedPhase 2ChimerixNCT00942305Written as Brincidofovir
- A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of CytomegalovirusTerminatedPhase 3ChimerixNCT02439957Written as Brincidofovir
- A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus DiseaseTerminatedPhase 3ChimerixNCT02439970Written as Brincidofovir
- Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy SubjectsCompletedPhase 1SymBio PharmaceuticalsNCT04542252Written as SyB V-1901
- The AdAPT Trial; Adenovirus After Allogeneic Pediatric TransplantationTerminatedPhase 2ChimerixNCT03339401Written as Brincidofovir
- An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of EbolaWithdrawnPhase 2ChimerixNCT04268966Written as Brincidofovir
- A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).CompletedPhase 1ViiV HealthcareNCT01563328Written as BCV
Codes
What other systems call brincidofovir · ClinicalTrials.gg INT005211
- MeSH (NLM) C525733brincidofovirConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 6794O900AXBRINCIDOFOVIRConfirmed FDA, NLM, Wikidata
- RxNorm 2599518One source FDA
- Wikidata Q15411004brincidofovirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C90587BrincidofovirOne source FDA
- DrugBank DB12151One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C525733 | brincidofovir | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 6794O900AX | BRINCIDOFOVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2599518 | — | One source FDA |
| Wikidata | Q15411004 | brincidofovir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C90587 | Brincidofovir | One source FDA |
| DrugBank | DB12151 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.